Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cancer Letters

• Publication date

  2007-07-08

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.CANLET.2006.12.013PMID 17223257
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Early effects of topoisomerase I inhibition on RNA polymerase II along transcribed genes in human cells.

  2006cited by this paper
• メシル酸イマチニブ(STI571)はBCR/ABLキナーゼ仲介DNA修復の阻害によってヒトK562慢性骨髄性白血病細胞でのドキソルビシンに対する耐性を無効にする

  2006cited by this paper
• Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma

  2006cited by this paper
• The association of DNA-dependent protein kinase activity with chromosomal instability and risk of cancer.

  2006cited by this paper
• The DNA repair complex DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy.

  2006cited by this paper
• The biology of Ku and its potential oncogenic role in cancer.

  2006cited by this paper
• BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells.

  2006cited by this paper
• Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.

  2006cited by this paper
• Glioblastoma cells deficient in DNA‐dependent protein kinase are resistant to cell death

  2005cited by this paper
• Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway.

  2005cited by this paper
• An in vitro model system that can differentiate the stages of DNA replication affected by anticancer agents.

  2004cited by this paper
• Downregulation of BRCA1 in A375 melanoma cell line increases radio-sensitivity and modifies metastatic and angiogenic gene expression.

  2004cited by this paper
• Biology of Chronic Myeloid Leukemia and Possible Therapeutic Approaches to Imatinib-Resistant Disease

  2004cited by this paper
• BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks.

  2004cited by this paper
• A Bcr/Abl-independent, Lyn-dependent Form of Imatinib Mesylate (STI-571) Resistance Is Associated with Altered Expression of Bcl-2*

  2004cited by this paper
• Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes.

  2004cited by this paper
• Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

  2004cited by this paper
• Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins.

  2003cited by this paper
• Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance?

  2003cited by this paper
• DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer.

  2003cited by this paper
• Ku70 suppresses the apoptotic translocation of Bax to mitochondria

  2003cited by this paper
• Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

  2002cited by this paper
• Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.

  2002cited by this paper
• Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571

  2002cited by this paper
• The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR–ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents

  2002cited by this paper
• Sensing and repairing DNA double-strand breaks.

  2002cited by this paper
• Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin.

  2002cited by this paper
• DOES THE BCR/ABL‐MEDIATED INCREASE IN THE EFFICACY OF DNA REPAIR PLAY A ROLE IN THE DRUG RESISTANCE OF CANCER CELLS?

  2002cited by this paper
• Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia

  2002cited by this paper
• Rational therapeutic intervention in cancer: kinases as drug targets.

  2002cited by this paper
• Changes in BRCA1 and BRCA2 expression produced by chemotherapeutic agents in human breast cancer cells.

  2002cited by this paper
• BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability

  2002cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.

  2001cited by this paper
• Modulation of camptothecin analogs in the treatment of cancer: a review

  2001cited by this paper
• Homologous and non‐homologous recombination differentially affect DNA damage repair in mice

  2000cited by this paper
• Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.

  2000cited by this paper
• Requirement for the Kinase Activity of Human DNA-Dependent Protein Kinase Catalytic Subunit in DNA Strand Break Rejoining

  1999cited by this paper
• Replication‐mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA‐dependent protein kinase and dissociates RPA:DNA‐PK complexes

  1999cited by this paper
• Ku autoantigen affects the susceptibility to anticancer drugs.

  1999cited by this paper
• Cross-resistance to ionizing radiation in a murine leukemic cell line resistant to cis-dichlorodiammineplatinum(II): role of Ku autoantigen.

  1999cited by this paper
• Differential etoposide sensitivity of cells deficient in the Ku and DNA-PKcs components of the DNA-dependent protein kinase.

  1998cited by this paper
• A REVIEW OF THE CLINICAL EXPERIENCE WITH IRINOTECAN (CPT‐11)

  1997cited by this paper
• Regulation of DNA-dependent protein kinase activity in leukemic cells

  1997cited by this paper
• Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.

  1996cited by this paper
• Modulation of thermal induction of hsp70 expression by Ku autoantigen or its individual subunits

  1996cited by this paper
• Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.

  1995cited by this paper

• Paris Saponin VII Induces Apoptosis and Cell Cycle Arrest in Erythroleukemia Cells by a Mitochondrial Membrane Signaling Pathway.

  2020cites this paper
• Natural Products for Treatment of Chronic Myeloid Leukemia

  2016cites this paper
• Camptothecin resistance in cancer: insights into the molecular mechanisms of a DNA-damaging drug.

  2013cites this paper
• Nuclear ErbB4 signaling through H3K9me3 is antagonized by EGFR-activated c-Src

  2013cites this paper
• Activation of abl family kinases in solid tumors.

  2012cites this paper
• 9-Methoxycamptothecin from Nothapodytes foetida Induces Apoptosis in Murine Sarcoma S180 Cells

  2011influential citation
• Investigating a co-operative link between TGF-β and Lyn kinase in Chronic Myeloid Leukaemia

  2011cites this paper
• Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91.

  2010cites this paper
• Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation.

  2010cites this paper
• Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.

  2009cites this paper
• PTPROt Inactivates the Oncogenic Fusion Protein BCR/ABL and Suppresses Transformation of K562 Cells*

  2009cites this paper
• Myeloid disease Who to transplant with chronic myelocytic leukemia in the tyrosine kinase era

  year unknowncites this paper